PMID- 36758579
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230403
IS  - 1540-1413 (Electronic)
IS  - 1540-1405 (Linking)
VI  - 21
IP  - 3
DP  - 2023 Feb 9
TI  - Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer 
      Treated With BRAF/MEK Inhibition.
PG  - 232-234
LID - 10.6004/jnccn.2022.7084 [doi]
AB  - BRAF/MEK inhibition remains standard of care for treatment of BRAF-mutated 
      non-small cell lung cancer (NSCLC). Although common adverse events (AEs) have 
      been reported through clinical trials and ongoing clinical practice, only a 
      handful of reports have detailed unusual adverse events associated with these 
      medications. This report presents a patient with BRAF-mutated NSCLC treated with 
      dabrafenib and trametinib who experienced 2 unusual AEs-Sweet syndrome and 
      MEK-associated retinopathy-that responded to steroid treatment. The patient was 
      able to continue BRAF/MEK inhibition through a coordinated multidisciplinary 
      approach. This case highlights the importance for all clinicians to recognize 
      unusual AEs associated with BRAF/MEK inhibition, particularly in the setting of 
      expanded use for all BRAF V600E-mutated solid tumors.
FAU - Maniar, Rohan
AU  - Maniar R
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical 
      Center, New York, New York.
FAU - Gallitano, Stephanie M
AU  - Gallitano SM
AD  - Department of Dermatology, Columbia University Irving Medical Center, New York, 
      New York.
FAU - Husain, Sameera
AU  - Husain S
AD  - Department of Dermatology, Columbia University Irving Medical Center, New York, 
      New York.
FAU - Moazami, Golnaz
AU  - Moazami G
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical 
      Center, New York, New York.
AD  - Harkness Eye Center, New York, New York.
FAU - Weiss, Michael J
AU  - Weiss MJ
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical 
      Center, New York, New York.
AD  - Harkness Eye Center, New York, New York.
FAU - Shu, Catherine A
AU  - Shu CA
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical 
      Center, New York, New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Compr Canc Netw
JT  - Journal of the National Comprehensive Cancer Network : JNCCN
JID - 101162515
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - 0 (Oximes)
RN  - EC 2.7.11.1 (BRAF protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - *Lung Neoplasms/drug therapy
MH  - Mitogen-Activated Protein Kinase Kinases/therapeutic use
MH  - Oximes/therapeutic use
MH  - Mutation
OTO - NOTNLM
OT  - BRAF mutation
OT  - Dabrafenib
OT  - Retinopathy
OT  - Sweet's Syndrome
OT  - Trametinib
EDAT- 2023/02/10 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/02/09 18:53
PHST- 2022/06/27 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2023/02/10 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/02/09 18:53 [entrez]
AID - 10.6004/jnccn.2022.7084 [doi]
PST - ppublish
SO  - J Natl Compr Canc Netw. 2023 Feb 9;21(3):232-234. doi: 10.6004/jnccn.2022.7084.